Jennison Associates
ASND icon

Jennison Associates’s Ascendis Pharma A/S ASND Stock Holding History

Jennison Associates’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-159,434
Closed -$14.9M – 588
2023
Q3 		$14.9M Buy
159,434
+37,363
+31% +$3.5M 0.01% 339
2023
Q2 		$10.9M Buy
122,071
+108,991
+833% +$9.49M 0.01% 372
2023
Q1 		$1.4M Sell
13,080
-580
-4% -$66.4K ﹤0.01% 470
2022
Q4 		$1.67M Sell
13,660
-499
-4% -$57.9K ﹤0.01% 451
2022
Q3 		$1.46M Buy
+14,159
New +$1.34M ﹤0.01% 474

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Jennison Associates's ASND Position: Q4 2023 in Review

Jennison Associates sold out of Ascendis Pharma A/S (ASND) in Q4 2023, closing a stake of 159,434 shares — an estimated $14.9M sold.

Jennison Associates first reported a position in ASND in Q3 2022 and held it in 5 quarters. The position peaked at $14.9M in Q3 2023. 185 funds tracked by Wall St. Rank hold ASND as of Q4 2023.

  • Jennison Associates reported no remaining Ascendis Pharma A/S position as of Q4 2023 after selling out during the quarter.
  • Jennison Associates sold 159,434 Ascendis Pharma A/S shares in Q4 2023, an estimated $14.9M.
  • Jennison Associates first reported a position in Ascendis Pharma A/S in Q3 2022 and held it in 5 quarters.
  • Jennison Associates's Ascendis Pharma A/S position peaked at $14.9M in Q3 2023.
  • 185 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2023.

Based on Jennison Associates's 13F filing for Q4 2023, filed 1 Feb 2024.